QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances AI-Powered GMP Manufacturing Platform
Oncotelic Therapeutics (OTCQB: OTLC) announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, advancing commercialization of an AI-powered good manufacturing practices manufacturing services platform at SAPU Bio, the company's 45%-owned sterile injectable cGMP manufacturing joint venture. The Phase 2 deployment expands the capabilities of Oncotelic's proprietary PDAOAI(TM) platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement. The company said the integrated platform combines PDAOAI(TM) with TechForce's autonomous robotic systems to support intelligent pharmaceutical manufacturing and create potential opportunities in software licensing, automation deployment, manufacturing partnerships…